A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：552

作者：

Bekker, PJ

Holloway, DL

Rasmussen, AS

Murphy, R

Martin, SW

Leese, PT

Holmes, GB

Dunstan, CR

DePaoli, AM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Quintiles, Lenexa, KS USA

[3] SFBC Int Inc, Miami, FL USA

[4] ANZAC Res Inst, Concord, NSW, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 07期

关键词：

RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;

D O I：

10.1359/JBMR.040305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.

引用

页码：1059 / 1066

页数：8

共 50 条

[1] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].

Anderson, DM ;

Maraskovsky, E ;

Billingsley, WL ;

Dougall, WC ;

Tometsko, ME ;

Roux, ER ;

Teepe, MC ;

DuBose, RF ;

Cosman, D ;

Galibert, L .

NATURE, 1997, 390 (6656) :175-179

[2] Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone [J].

Atkins, GJ ;

Bouralexis, S ;

Haynes, DR ;

Graves, SE ;

Geary, SM ;

Evdokiou, A ;

Zannettino, ACW ;

Hay, S ;

Findlay, DM .

BONE, 2001, 28 (04) :370-377

[3] The effect of a single dose of osteoprotegerin in postmenopausal women [J].

Bekker, PJ ;

Holloway, D ;

Nakanishi, A ;

Arrighi, M ;

Leese, PT ;

Dunstan, CR .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360

[4] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[5] Osteoprotegerin and rank ligand expression in prostate cancer [J].

Brown, JM ;

Corey, E ;

Lee, ZD ;

True, LD ;

Yun, TJ ;

Tondravi, M ;

Vessella, RL .

UROLOGY, 2001, 57 (04) :611-616

[6] The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis [J].

Brown, JP ;

Kendler, DL ;

McClung, MR ;

Emkey, RD ;

Adachi, JD ;

Bolognese, MA ;

Li, Z ;

Balske, A ;

Lindsay, R .

CALCIFIED TISSUE INTERNATIONAL, 2002, 71 (02) :103-111

[7] osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].

Bucay, N ;

Sarosi, I ;

Dunstan, CR ;

Morony, S ;

Tarpley, J ;

Capparelli, C ;

Scully, S ;

Tan, HL ;

Xu, WL ;

Lacey, DL ;

Boyle, WJ ;

Simonet, WS .

GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268

[8] The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts [J].

Burgess, TL ;

Qian, YX ;

Kaufman, S ;

Ring, BD ;

Van, G ;

Capparelli, C ;

Kelley, M ;

Hsu, HL ;

Boyle, WJ ;

Dunstan, CR ;

Hu, S ;

Lacey, DL .

JOURNAL OF CELL BIOLOGY, 1999, 145 (03) :527-538

[9] Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density [J].

Chesnut, CH ;

Bell, NH ;

Clark, GS ;

Drinkwater, BL ;

English, SC ;

Johnston, CC ;

Notelovitz, M ;

Rosen, C ;

Cain, DF ;

Flessland, KA ;

Mallinak, NJS .

AMERICAN JOURNAL OF MEDICINE, 1997, 102 (01) :29-37

[10] Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice [J].

Clohisy, DR ;

Ramnaraine, ML ;

Scully, S ;

Qi, MY ;

Van, G ;

Tan, HL ;

Lacey, DL .

JOURNAL OF ORTHOPAEDIC RESEARCH, 2000, 18 (06) :967-976

← 1 2 3 4 5 →